ENZN
$0.24
Enzon Pharma
$.01
2.74%
ENZN
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Wednesday
Oct 28
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when ENZN reports earnings?
Beat
Meet
Miss

Where is ENZN's stock price going from here?
Up
Flat
Down
Stock chart of ENZN
Analysts
Summary of analysts' recommendations for ENZN
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.